CORE beneficiary partner Syncom and Mercachem, two of the leading European drug discovery Contract Research Organizations (CRO), today announced that the two companies are joining forces effective immediately. The resulting Mercachem-Syncom Group, with more than 300 employees and operations in Nijmegen and Groningen, the Netherlands and Prague, Czech Republic, becomes the premier European mid-sized CRO offering innovative best-in-class chemistry solutions.
Since their inception in 1997 and 1988 respectively, Mercachem and Syncom have established themselves as two of Europe’s leading drug discovery CROs with a focus on high-quality chemistry services to large and mid-size pharmaceutical, life sciences and innovative chemistry customers worldwide. Today’s merger enables the Mercachem-Syncom Group to broaden its offering of integrated drug discovery services and invest into state-of-the-art knowledge base and facilities to address clients’ growing demand for outsourcing solutions. The merger of Mercachem and Syncom and the Group’s growth strategy with a further expansion both organically as well as through partnerships and further acquisitions is supported by Gilde Healthcare, a leading investor in healthcare together with Dutch pension fund service provider PGGM, as co-investor.
See full press release at https://syncom.nl/mercachem-and-syncom-join-forces/
Free WEBINAR - The Influence of Crystallization Kinetics on Your Process
This Free Technobis webinar, presented by Prof. Dr. Joop ter Horst, will look at how crystallization kinetics influence you crystallization process..... more
CORE's Prof. Seidel-Morgenstern invited as plenary speaker at the first European Asymmetry Symposium
The first European Asymmetry Symposium unites economists, physicists and artists..... more